- Bionano Genomics unveils a groundbreaking study in multiple myeloma analysis via optical genome mapping (OGM).
- Analysts predict a significant upside potential with a one-year price target of $7.00 for BNGO.
- GuruFocus' GF Value estimates a staggering 9983.06% increase from BNGO's current trading price.
Bionano Genomics (BNGO, Financial) has announced a revolutionary study that showcases an enhanced method for analyzing multiple myeloma using optical genome mapping (OGM). This advanced technique notably reduces the number of required CD138-positive cells. This development could notably expand research capabilities within hematologic malignancies, offering significant implications for future research.
Wall Street Analysts' Insight
Wall Street analysts provide valuable forecasts for Bionano Genomics Inc (BNGO, Financial). Currently, two analysts have set a one-year average price target of $7.00, with a high estimate reaching $10.00 and a low at $4.00. This average target reflects a potential upside of 88.17% from the current price of $3.72. For further details on these estimates, explore the Bionano Genomics Inc (BNGO) Forecast page.
Additionally, the consensus recommendation from three brokerage firms positions Bionano Genomics Inc's (BNGO, Financial) average recommendation at 2.7, which indicates a "Hold" status. The rating scale extends from 1, suggesting a Strong Buy, to 5, indicating Sell.
GuruFocus GF Value Estimation
Under the lens of GuruFocus estimates, the anticipated GF Value for Bionano Genomics Inc (BNGO, Financial) in the upcoming year is projected at $375.09. This suggests an extraordinary upside of 9983.06% from its present trading price of $3.72. The GF Value represents GuruFocus' evaluation of the stock's fair value, developed from historical trading multiples, past business growth, and prospective business performance forecasts. More intricate data can be accessed on the Bionano Genomics Inc (BNGO) Summary page.
